Literature DB >> 16625717

Immunity's yin and yang. A successful vaccine must first avoid being eliminated by pre-existing immunity before it can promote a protective immune response.

Philip Cohen.   

Abstract

Mesh：

Substances：

Year:  2006        PMID： 16625717

Source DB:  PubMed          Journal:  IAVI Rep        ISSN： 1816-6253


× No keyword cloud information.
  12 in total

1.  A live attenuated Listeria monocytogenes vaccine vector expressing SIV Gag is safe and immunogenic in macaques and can be administered repeatedly.

Authors:  Gaia Sciaranghella; Samir K Lakhashe; Mila Ayash-Rashkovsky; Saied Mirshahidi; Nagadenahalli B Siddappa; Francis J Novembre; Vijayakumar Velu; Rama Rao Amara; Chenghui Zhou; Sufen Li; Zhongxia Li; Fred R Frankel; Ruth M Ruprecht
Journal:  Vaccine       Date:  2010-11-09       Impact factor: 3.641

Review 2.  Human immunodeficiency virus type 1 vaccine development: recent advances in the cytotoxic T-lymphocyte platform "spotty business".

Authors:  Kimberly A Schoenly; David B Weiner
Journal:  J Virol       Date:  2007-11-07       Impact factor: 5.103

3.  Two complex, adenovirus-based vaccines that together induce immune responses to all four dengue virus serotypes.

Authors:  David H Holman; Danher Wang; Kanakatte Raviprakash; Nicholas U Raja; Min Luo; Jianghui Zhang; Kevin R Porter; John Y Dong
Journal:  Clin Vaccine Immunol       Date:  2006-12-27

4.  A complex adenovirus vaccine against chikungunya virus provides complete protection against viraemia and arthritis.

Authors:  Danher Wang; Andreas Suhrbier; Adam Penn-Nicholson; Jan Woraratanadharm; Joy Gardner; Min Luo; Thuy T Le; Itaru Anraku; Michael Sakalian; David Einfeld; John Y Dong
Journal:  Vaccine       Date:  2011-02-12       Impact factor: 3.641

5.  A complex adenovirus-vectored vaccine against Rift Valley fever virus protects mice against lethal infection in the presence of preexisting vector immunity.

Authors:  David H Holman; Adam Penn-Nicholson; Danher Wang; Jan Woraratanadharm; Mary-Katherine Harr; Min Luo; Ellen M Maher; Michael R Holbrook; John Y Dong
Journal:  Clin Vaccine Immunol       Date:  2009-09-23

6.  Vaccine to confer to nonhuman primates complete protection against multistrain Ebola and Marburg virus infections.

Authors:  Dana L Swenson; Danher Wang; Min Luo; Kelly L Warfield; Jan Woraratanadharm; David H Holman; John Y Dong; William D Pratt
Journal:  Clin Vaccine Immunol       Date:  2008-01-23

7.  A tetravalent dengue vaccine based on a complex adenovirus vector provides significant protection in rhesus monkeys against all four serotypes of dengue virus.

Authors:  Kanakatte Raviprakash; Danher Wang; Dan Ewing; David H Holman; Karla Block; Jan Woraratanadharm; Lan Chen; Curtis Hayes; John Y Dong; Kevin Porter
Journal:  J Virol       Date:  2008-05-14       Impact factor: 5.103

8.  Complex adenovirus-mediated expression of West Nile virus C, PreM, E, and NS1 proteins induces both humoral and cellular immune responses.

Authors:  Jennifer Schepp-Berglind; Min Luo; Danher Wang; Jason A Wicker; Nicholas U Raja; Brian D Hoel; David H Holman; Alan D T Barrett; John Y Dong
Journal:  Clin Vaccine Immunol       Date:  2007-07-18

9.  Effect of preexisting immunity to adenovirus human serotype 5 antigens on the immune responses of nonhuman primates to vaccine regimens based on human- or chimpanzee-derived adenovirus vectors.

Authors:  Kimberly McCoy; Nia Tatsis; Birgit Korioth-Schmitz; Marcio O Lasaro; Scott E Hensley; Shih-Wen Lin; Yan Li; Wynetta Giles-Davis; Ann Cun; Dongming Zhou; Zhiquan Xiang; Norman L Letvin; Hildegund C J Ertl
Journal:  J Virol       Date:  2007-04-11       Impact factor: 5.103

10.  Impact of preexisting vector-specific immunity on vaccine potency: characterization of listeria monocytogenes-specific humoral and cellular immunity in humans and modeling studies using recombinant vaccines in mice.

Authors:  Meredith L Leong; Johannes Hampl; Weiqun Liu; Shruti Mathur; Keith S Bahjat; William Luckett; Thomas W Dubensky; Dirk G Brockstedt
Journal:  Infect Immun       Date:  2009-06-15       Impact factor: 3.441
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.